search
Back to results

Olorofim Aspergillus Infection Study (OASIS)

Primary Purpose

Invasive Aspergillosis

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Olorofim
AmBisome®
Sponsored by
F2G Biotech GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Invasive Aspergillosis focused on measuring Invasive fungal disease (IFD), Aspergillus species, Olorofim, Non-azole antifungal, Azole resistance

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female patients ages over 18 years and weighing more than 40 kg
  2. Patients with proven IA at any site or probable LRTD IA per EORTC/MSG 2019 criteria as adapted for this study
  3. Patients requiring therapy with an antifungal agent other than a mould-active azole on the basis of IA refractory to mould-active azole therapy, proven resistance to the mould active azoles, breakthrough infection on mould-active triazole prophylaxis, or azole drug-drug interactions (or potential for drug-drug interactions).
  4. AmBisome® is an appropriate therapy for the patient.

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug
  3. Patients with only chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
  4. Suspected mucormycosis (zygomycosis).
  5. Patients with a known active second fungal infection of any type, other than candidiasis that can be treated with fluconazole.
  6. The use of an echinocandin as Candida prophylaxis.
  7. Microbiological findings (eg, bacteriological, virological) or other potential conditions that are temporally related and suggest a different aetiology for the clinical features.
  8. Human immunodeficiency virus (HIV) infection but not currently receiving antiretroviral therapy.
  9. Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥ 500 msec, or at high risk for QT/QTc prolongation.
  10. Evidence of hepatic dysfunction.

Sites / Locations

  • University of California Davis Health SystemRecruiting
  • UCSF Helen Diller Medical Center at Parnassus HeightsRecruiting
  • NIH Clinical Center ,NIAID,NIHRecruiting
  • Washington University School of MedicineRecruiting
  • Clairvoyant Research Group, LLC
  • University of Pittsburgh Medical Center Health SystemRecruiting
  • Fred Hutchinson Cancer CenterRecruiting
  • Royal Melbourne HospitalRecruiting
  • The Alfred HospitalRecruiting
  • Fiona Stanley HospitalRecruiting
  • Universitair Ziekenhuis GentRecruiting
  • UZ LeuvenRecruiting
  • Universitair Ziekenhuis GentRecruiting
  • Hospital Felício RochoRecruiting
  • Santa Casa de Misericórdia de Belo HorizonteRecruiting
  • Santa Casa de Misericórdia de PassosRecruiting
  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao CâncerRecruiting
  • Irmandade da Santa Casa de Misericórdia de Porto AlegreRecruiting
  • Hospital de Clínicas de Porto AlegreRecruiting
  • Hospital São Lucas da PUCRSRecruiting
  • Hospital da Universidade Federal de Santa Maria CEP/UFSMRecruiting
  • University of Alberta HospitalRecruiting
  • Hamilton Health Sciences - Juravinski SiteRecruiting
  • Institut de Cancérologie de Strasbourg Europe - ICANSRecruiting
  • CHU Besançon - Hôpital Jean MinjozRecruiting
  • Hôpital Necker - Enfants MaladesRecruiting
  • Soroka University Medical CenterRecruiting
  • Hadassah University Hospital - Ein KeremRecruiting
  • Chaim Sheba Medical CenterRecruiting
  • Tel Aviv Sourasky Medical Center PtRecruiting
  • Radboud NijmegenRecruiting
  • UMC UtrechtRecruiting
  • National University HospitalRecruiting
  • Singapore General Hospital- ParentRecruiting
  • Hospital Universitari Vall d'HebronRecruiting
  • Hospital Universitario Ramon y CajalRecruiting
  • Hospital Universitari i Politecnic La FeRecruiting
  • Kaohsiung Medical University Chung-Ho Memorial HospitalRecruiting
  • Taipei Medical University - Shuang Ho Hospital, Ministry of Health and WelfareRecruiting
  • National Taiwan University HospitalRecruiting
  • Siriraj HospitalRecruiting
  • King Chulalongkorn Memorial HospitalRecruiting
  • Srinagarind HospitalRecruiting
  • Hacettepe University Medical FacultyRecruiting
  • Ankara City HospitalRecruiting
  • Dicle University, Medical FacultyRecruiting
  • Acibadem Atakent HospitalRecruiting
  • Ege University Medical FacultyRecruiting
  • Ondokuz Mayis Univ. Med. Fac.Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Olorofim

AmBisome

Arm Description

Olorofim versus AmBisome followed by Standard of Care (SOC)

Olorofim versus AmBisome followed by Standard of Care (SOC)

Outcomes

Primary Outcome Measures

All-cause mortality
To compare all-cause mortality (ACM) at Day 42 following treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in the intent-to-treat (ITT) population of patients with Invasive Fungal Disease (IFD) caused by proven Invasive Aspergillosis (IA) or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).

Secondary Outcome Measures

Adjudicated Assessment of Overall outcome
To compare the effects of treatment with olorofim versus treatment with AmBisome® followed by SOC on Data Review Committee (DRC)-adjudicated assessment of overall outcome in patients with proven IA or probable LRTD IA at Day 42, Day 84, and End of Treatment (anytime during the study between first administration and Day 84).
Investigator-assessed overall response
To compare the effects of treatment with olorofim versus treatment with AmBisome® followed by SOC on Investigator integrated assessessment of clinical signs and symptoms, radiological response and mycological response related to the IFD caused by Aspergillus species.
Safety Assessment
To monitor incidence of Adverse Events and Serious Adverse Events in both treatment arms (Olorofim or AmBisome followed by Standard of Care).

Full Information

First Posted
September 7, 2021
Last Updated
May 31, 2023
Sponsor
F2G Biotech GmbH
Collaborators
Iqvia Pty Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05101187
Brief Title
Olorofim Aspergillus Infection Study
Acronym
OASIS
Official Title
Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 31, 2022 (Actual)
Primary Completion Date
September 14, 2024 (Anticipated)
Study Completion Date
March 4, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
F2G Biotech GmbH
Collaborators
Iqvia Pty Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Detailed Description
The mortality rate in immunosuppressed patients with IA is high even with effective modern antifungal drug treatment. Intrinsic and acquired resistance to azoles and amphotericin B, the two most effective classes of treatment, have been identified in Aspergillus species and are linked to this increased mortality. Currently marketed antifungal drugs have limitations including limited dosage forms, DDIs, and significant adverse reactions. For patients with IA who do not respond to or cannot tolerate a triazole therapy, treatment options are even more limited. Olorofim is an antifungal candidate with a novel mechanism of action offering activity against resistant organisms, differences in safety profile, along with oral dosing, predictable and reliable pharmacokinetic (PK) profile and limited potential for DDIs. The present study is designed to compare the efficacy, safety, and tolerability of olorofim with that of AmBisome® followed by guideline-based hierarchy standard of care (SOC) in patients with IA whose infection is either refractory to or unsuitable for azole therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Invasive Aspergillosis
Keywords
Invasive fungal disease (IFD), Aspergillus species, Olorofim, Non-azole antifungal, Azole resistance

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Investigator
Masking Description
Adjudicator and sponsor-blinded.
Allocation
Randomized
Enrollment
225 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Olorofim
Arm Type
Active Comparator
Arm Description
Olorofim versus AmBisome followed by Standard of Care (SOC)
Arm Title
AmBisome
Arm Type
Active Comparator
Arm Description
Olorofim versus AmBisome followed by Standard of Care (SOC)
Intervention Type
Drug
Intervention Name(s)
Olorofim
Other Intervention Name(s)
Olorofim (F901318)
Intervention Description
Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
Intervention Type
Drug
Intervention Name(s)
AmBisome®
Other Intervention Name(s)
AmBisome® (liposomal amphotericin B)
Intervention Description
Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
Primary Outcome Measure Information:
Title
All-cause mortality
Description
To compare all-cause mortality (ACM) at Day 42 following treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in the intent-to-treat (ITT) population of patients with Invasive Fungal Disease (IFD) caused by proven Invasive Aspergillosis (IA) or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Time Frame
Treatment Day 42
Secondary Outcome Measure Information:
Title
Adjudicated Assessment of Overall outcome
Description
To compare the effects of treatment with olorofim versus treatment with AmBisome® followed by SOC on Data Review Committee (DRC)-adjudicated assessment of overall outcome in patients with proven IA or probable LRTD IA at Day 42, Day 84, and End of Treatment (anytime during the study between first administration and Day 84).
Time Frame
Day 42, Day 84, and End of Treatment (anytime during the study between first administration and Day 84)
Title
Investigator-assessed overall response
Description
To compare the effects of treatment with olorofim versus treatment with AmBisome® followed by SOC on Investigator integrated assessessment of clinical signs and symptoms, radiological response and mycological response related to the IFD caused by Aspergillus species.
Time Frame
Day 14, Day 28, Day 42, Day 84, End of Treatment (anytime during the study between first administration and Day 84) and 4-week Follow-up (FU)
Title
Safety Assessment
Description
To monitor incidence of Adverse Events and Serious Adverse Events in both treatment arms (Olorofim or AmBisome followed by Standard of Care).
Time Frame
up to the Day 84 and 4-week Follow-up (FU)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients ages over 18 years and weighing more than 40 kg Patients with proven IA at any site or probable LRTD IA per EORTC/MSG 2019 criteria as adapted for this study Patients requiring therapy with an antifungal agent other than a mould-active azole on the basis of IA refractory to mould-active azole therapy, proven resistance to the mould active azoles, breakthrough infection on mould-active triazole prophylaxis, or azole drug-drug interactions (or potential for drug-drug interactions). AmBisome® is an appropriate therapy for the patient. Exclusion Criteria: Women who are pregnant or breastfeeding. Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug Patients with only chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis. Suspected mucormycosis (zygomycosis). Patients with a known active second fungal infection of any type, other than candidiasis that can be treated with fluconazole. The use of an echinocandin as Candida prophylaxis. Microbiological findings (eg, bacteriological, virological) or other potential conditions that are temporally related and suggest a different aetiology for the clinical features. Human immunodeficiency virus (HIV) infection but not currently receiving antiretroviral therapy. Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥ 500 msec, or at high risk for QT/QTc prolongation. Evidence of hepatic dysfunction.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniela Zinzi, MD
Phone
+43 06643582281
Email
DZinzi@f2g.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Johan Maertens, MD
Organizational Affiliation
UZ Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California Davis Health System
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thompson, George Thompson, George, Dr.
Phone
916-734-3815
Email
grthompson@ucdavis.edu
Facility Name
UCSF Helen Diller Medical Center at Parnassus Heights
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Doernberg
Phone
415-502-5548
Email
sarah.doernberg@ucsf.edu
Facility Name
NIH Clinical Center ,NIAID,NIH
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Holland
Phone
301-496-1465
Email
sholland@niaid.nih.gov
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrej Spec
Phone
314-454-8354
Email
andrejspec@wustl.edu
Facility Name
Clairvoyant Research Group, LLC
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Individual Site Status
Terminated
Facility Name
University of Pittsburgh Medical Center Health System
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hong Nguyen, Dr.
Phone
412-383-5193
Email
mhn5@pitt.edu
Facility Name
Fred Hutchinson Cancer Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109-1024
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Pergam
Phone
206-667-7538
Email
spergam@fhcrc.org
Facility Name
Royal Melbourne Hospital
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monica Slavin, Dr.
Phone
+61393427000
Email
monica.slavin@mh.org.au
First Name & Middle Initial & Last Name & Degree
Monica Slavin, Dr.
Facility Name
The Alfred Hospital
City
Prahan
State/Province
Victoria
ZIP/Postal Code
3181
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Orla Morrissey, Dr
Phone
+61390762631
Email
o.morrissey@alfred.org.au
First Name & Middle Initial & Last Name & Degree
Orla Morrissey, Dr
Facility Name
Fiona Stanley Hospital
City
Murdoch
State/Province
Western Australia
ZIP/Postal Code
6150
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chris Heath, Dr
Phone
+61892241989
Email
chris.heath@health.wa.gov.au
First Name & Middle Initial & Last Name & Degree
Chris Heath, Dr
Facility Name
Universitair Ziekenhuis Gent
City
Gent
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Van Braeckel, Dr.
Phone
+3293323861
Email
eva.vanbraeckel@ugent.be
First Name & Middle Initial & Last Name & Degree
Eva Van Braeckel, Dr.
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johan Maertens, Dr.
Phone
+3216346887
Email
johan.maertens@uzleuven.be
First Name & Middle Initial & Last Name & Degree
Johan Maertens, Dr
Facility Name
Universitair Ziekenhuis Gent
City
Vila Geni
State/Province
Belgium
ZIP/Postal Code
9000
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Van Braeckel, Prof
Phone
+3293323861
Email
eva.vanbraeckel@ugent.be
Facility Name
Hospital Felício Rocho
City
Belo Horizonte
State/Province
Minas Gerais
ZIP/Postal Code
30110-934
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adelino Freire Junior, Dr.
Phone
+553135147195
Email
adelinomelo@gmail.com.br
Facility Name
Santa Casa de Misericórdia de Belo Horizonte
City
Belo Horizonte
State/Province
Minas Gerais
ZIP/Postal Code
30150-221
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antônio Tarcísio de Faria Freire, Dr.
Phone
+553132388270
Email
antonio.freire@santacasapesquisa.com.br
Facility Name
Santa Casa de Misericórdia de Passos
City
Passos
State/Province
Minas Gerais
ZIP/Postal Code
37904-020
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Priscila Freitas Neves Goncalves, Dr
Phone
+553535291457
Email
prifreitas@yahoo.com.br
Facility Name
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
City
Curitiba
State/Province
Paraná
ZIP/Postal Code
81520-060
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manuel Paz Morales, Hugo
Phone
+554133615133
Email
moraleshmp@gmail.com
Facility Name
Irmandade da Santa Casa de Misericórdia de Porto Alegre
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90020-090
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berdun Stadnik, Dr
Phone
+5551981212220
Email
cmstadnik@gmail.com
Facility Name
Hospital de Clínicas de Porto Alegre
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90035-903
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luciano Zubaran Goldani, Dr
Phone
+555121018617
Email
lgoldani@ufrgs.br
Facility Name
Hospital São Lucas da PUCRS
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90610-000
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabiano Ramos, Dr
Phone
+555133203345
Email
framos@pucrs.br
Facility Name
Hospital da Universidade Federal de Santa Maria CEP/UFSM
City
Santa Maria
State/Province
Rio Grande Do Sul
ZIP/Postal Code
97105-900
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandre Vargas Schwarzbold, Dr
Phone
+555532131482
Email
alexvspoa@gmail.com
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 2B7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dima Kabbani, Dr.
Phone
7804929418
Email
dkabbani@ualberta.ca
Facility Name
Hamilton Health Sciences - Juravinski Site
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 2X2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shariq Haider, Dr
Phone
9055236048
Email
haider@mcmaster.ca
Facility Name
Institut de Cancérologie de Strasbourg Europe - ICANS
City
Strasbourg
State/Province
Bas Rhin
ZIP/Postal Code
67200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raoul Herbrecht, Prof
Phone
+33388127681
Email
raoul.herbrecht@chru-strasbourg.fr
Facility Name
CHU Besançon - Hôpital Jean Minjoz
City
Besançon Cedex
State/Province
Doubs
ZIP/Postal Code
25030
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ana Berceanu, Dr.
Phone
+33381668351
Email
aberceanu@chu-besancon.fr
Facility Name
Hôpital Necker - Enfants Malades
City
Paris cedex 15
State/Province
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fanny Lanternier, Dr.
Phone
+33144495262
Email
fanny.lanternier@aphp.fr
Facility Name
Soroka University Medical Center
City
Beer-Sheva
ZIP/Postal Code
84001
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lior Nesher, Dr.
Phone
+972505226856
Email
liorne@clalit.org.il
Facility Name
Hadassah University Hospital - Ein Kerem
City
Jerusalem
ZIP/Postal Code
9112001
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maya Korem, Dr.
Phone
+97226419545
Email
mayak@hadassah.org.il
Facility Name
Chaim Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
5265601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Galia Rahav, Dr.
Phone
+97235303501
Email
galia.rahav@sheba.health.gov.il
Facility Name
Tel Aviv Sourasky Medical Center Pt
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ronen Ben-Ami, Dr.
Phone
+97236974996
Email
ronenba@tlvmc.gov.il
Facility Name
Radboud Nijmegen
City
Nijmegen
ZIP/Postal Code
6525GA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frank Van de Veerdonk, Dr.
Phone
+31243616980
Email
frank.vandeveerdonk@radboudumc.nl
Facility Name
UMC Utrecht
City
Utrecht
ZIP/Postal Code
3508 GA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anke Bruns, Dr.
Phone
+31887555639
Email
a.h.w.bruns@umcutrecht.nl
Facility Name
National University Hospital
City
Singapore
ZIP/Postal Code
117599
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chai Chai, Dr.
Phone
+6567795678
Email
louis_chai@nuhs.edu.sg
Facility Name
Singapore General Hospital- Parent
City
Singapore
ZIP/Postal Code
169608
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yvonne Chan, Dr.
Phone
+6592304293
Email
yvonne.chan.f.z@singhealth.com.sg
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabel Ruiz Camps, Dr.
Phone
+34932246090
Email
iruiz@vhebron.net
Facility Name
Hospital Universitario Ramon y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jesus Fortun Abete, Dr.
Phone
+34913368710
Email
fortunabete@gmail.com
Facility Name
Hospital Universitari i Politecnic La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amparo Sole Jover, Dr.
Phone
+34961246266
Email
sole_amp@gva.es
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Po-Liang Lu, Dr.
Phone
+8863119544
Email
d830166@gmail.com
Facility Name
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
City
New Taipei City
ZIP/Postal Code
23561
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yung-Ching Liu, Prof
Phone
+886222490088X8878
Email
yungchingliuster@gmail.com
Facility Name
National Taiwan University Hospital
City
Taipei
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yee-Chun Chen, Dr.
Phone
+886223971412 0-00-000000
Email
yeechunchen@gmail.com
Facility Name
Siriraj Hospital
City
Bangkok-noi
State/Province
Bangkok
ZIP/Postal Code
10700
Country
Thailand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Methee Chayakulkeeree, AProf
Phone
+6643203772
Email
methee.cha@mahidol.ac.th
Facility Name
King Chulalongkorn Memorial Hospital
City
Pathum Wan
State/Province
Bangkok
ZIP/Postal Code
10330
Country
Thailand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jutivorakool Kamonwan
Facility Name
Srinagarind Hospital
City
Khon Kaen
ZIP/Postal Code
40002
Country
Thailand
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mootsikapun, Piroon Mootsikapun, Piroon, AProf
Phone
+6643203772
Email
piroon_m@hotmail.com
Facility Name
Hacettepe University Medical Faculty
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Murat Akova, Prof
Phone
+903123104179
Email
akova@hacettepe.edu.tr
Facility Name
Ankara City Hospital
City
Ankara
ZIP/Postal Code
06800
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rahmet Guner, Prof
Phone
+05079921101 00000 000 00 00
Email
rahmetguner@yahoo.com
Facility Name
Dicle University, Medical Faculty
City
Diyarbakir
ZIP/Postal Code
21280
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mustafa Kemal Celen, Prof
Phone
+904122488440
Email
mkcelen@hotmail.com
Facility Name
Acibadem Atakent Hospital
City
Istanbul
ZIP/Postal Code
34303
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Iftihar Koksal, Prof
Phone
+05079921101 00000 000 00 00
Email
iftihar@yahoo.com
Facility Name
Ege University Medical Faculty
City
Izmir
ZIP/Postal Code
35100
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Husnu Pullukcu, Prof
Phone
+902323904775
Email
husnup@yahoo.com
Facility Name
Ondokuz Mayis Univ. Med. Fac.
City
Samsun
ZIP/Postal Code
55270
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ilkay Bozkurt, Dr.
Email
drilkaybozkurt@gmail.com

12. IPD Sharing Statement

Learn more about this trial

Olorofim Aspergillus Infection Study

We'll reach out to this number within 24 hrs